ArticleBiomaterials2013
Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Nanoparticle approaches for hepatitis therapy and clinical translation.Discover nano · 2026Review
- Outer membrane vesicles fromFrontiers in molecular biosciences · 2025Article
- Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation.Current research in pharmacology and drug discovery · 2025Review
- Magnetic Relaxation Switching Assay Using IFNα-2b-Conjugated Superparamagnetic Nanoparticles for Anti-Interferon Antibody Detection.Biosensors · 2023Article
- Antiviral Peptides in Antimicrobial Surface Coatings-From Current Techniques to Potential Applications.Viruses · 2023Review
- Broad-spectrum Respiratory Virus Entry Inhibitors.Advances in experimental medicine and biology · 2022Article
- Inorganic and Polymeric Nanoparticles for Human Viral and Bacterial Infections Prevention and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- Recent trends in click chemistry as a promising technology for virus-related research.Virus research · 2018Review
- Hepatitis C virus management: potential impact of nanotechnology.Virology journal · 2017Review
- Why whey? Camel whey protein as a new dietary approach to the management of free radicals and for the treatment of different health disorders.Iranian journal of basic medical sciences · 2017Review
- Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.Biomaterials · 2015Article
- Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus.BMC complementary and alternative medicine · 2014Article
- Peptidomimetics as a new generation of antimicrobial agents: current progress.Infection and drug resistance · 2014Review
- Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.Frontiers in microbiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
It is estimated that 4 to 5 million people are currently co-infected with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV). HIV/HCV co-infection is associated with unique health risks including increased hepatotoxicity of antiretrovirals, accelerated progression of HCV and liver diseases. The standard interferon-based therapy is effective only in about 50% of patients and often is associated with autoimmune and neuro-psychiatric complications. The treatment of co-infection (HIV/HCV) requires new strategic approaches. To this end, the formulations of an amphiphatic α-helical peptide, a positively charged analog of C5A peptide derived from the HCV NS5A protein, with a reported virocidal activity were prepared by electrostatic coupling with anionic poly(amino acid)-based block copolymers. The self-assembled antiviral peptide nanocomplexes (APN) were ca. 35 nm in size, stable at physiological pH and ionic strength, and retained in vitro antiviral activity against HCV and HIV. Moreover, incorporation of the peptide into APN attenuated its cytotoxicity associated with the positive charge. In vivo APN were able to decrease the viral load in mice transplanted with human lymphocytes and HIV-1-infected. Overall, these findings indicate the potential of these formulations for stabilization and delivery of antiviral peptides while maintaining their functional activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.